Repros Therapeutics Inc (RPRX)

0.46
0.07 17.95
NASDAQ : Health Care
Prev Close 0.39
Open 0.41
Day Low/High 0.39 / 0.48
52 Wk Low/High 0.80 / 8.96
Volume 1.63M
Avg Volume 360.00K
Exchange NASDAQ
Shares Outstanding 26.73M
Market Cap 10.96M
EPS -0.70
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Repros Announces Pricing Of $3.0 Million Public Offering Of Common Stock And Warrants To Purchase Common Stock

Repros Announces Proposed Public Offering Of Common Stock And Warrants To Purchase Common Stock

Repros Therapeutics Inc.® Reports First Quarter 2017 Financial Results

Repros Announces The Issuance Of New U.S. Patent Relating To Treatment Using Off Drug Intervals For Certain Uterine Conditions

Repros Names Larry Dillaha, M.D., Its Permanent President And CEO

Company Holds Meeting With FDA To Discuss Oral Proellex® In The Treatment Of Uterine Fibroids

Repros Therapeutics Inc.® Reports Fourth Quarter And Year End 2016 Financial Results

Biotech Stock Mailbag: Do Investors Have an 'Aphinity' for Shorting Puma Into Trial Results?

Biotech Stock Mailbag: Do Investors Have an 'Aphinity' for Shorting Puma Into Trial Results?

TheStreet's Adam Feuerstein answers reader questions about biotech stocks.

Repros Announces New CEO

Larry Dillaha, M.D., Named President and CEO on Interim Basis

FDA Grants End Of Phase 2 Meeting To Discuss Phase 3 Requirements For Oral Proellex® In The Treatment Of Uterine Fibroids

Repros Requests Meeting With FDA To Discuss Phase 3 Requirements For Proellex® In The Treatment Of Endometriosis

Repros Requests Meeting With FDA To Discuss Phase 3 Requirements For Proellex® In The Treatment Of Endometriosis

Repros Requests Meeting With FDA To Discuss Phase 3 Requirements For Proellex® In The Treatment Of Symptomatic Uterine Fibroids

Repros Requests Meeting With FDA To Discuss Phase 3 Requirements For Proellex® In The Treatment Of Symptomatic Uterine Fibroids

FDA Advisory Committee Discusses Clinical Trial Designs For Obesity-Related Hypogonadism

FDA Advisory Committee Discusses Clinical Trial Designs For Obesity-Related Hypogonadism

Repros Reports Topline Positive Clinical Data After Two 18 Week Courses Of Proellex® Delivered Orally And Vaginally For The Treatment Of Uterine Fibroids

Repros Reports Topline Positive Clinical Data After Two 18 Week Courses Of Proellex® Delivered Orally And Vaginally For The Treatment Of Uterine Fibroids

Repros Therapeutics Inc.® Reports Third Quarter 2016 Financial Results

Repros Therapeutics Inc.® Reports Third Quarter 2016 Financial Results

Repros Announces Acceptance Of Dossier For Enclomiphene For Secondary Hypogonadism By European Authorities

Repros Announces Acceptance Of Dossier For Enclomiphene For Secondary Hypogonadism By European Authorities

FDA Schedules Advisory Committee Meeting To Discuss Secondary Hypogonadism

FDA Schedules Advisory Committee Meeting To Discuss Secondary Hypogonadism

Repros Announces Submission Of MAA To The European Medicines Agency For Enclomiphene In The Treatment Of Secondary Hypogonadism

Repros Announces Submission Of MAA To The European Medicines Agency For Enclomiphene In The Treatment Of Secondary Hypogonadism

Repros Provides Phase 2 Results Showing Positive Outcomes For Oral Proellex® In Women With Moderate To Severe Endometriosis

Repros Provides Phase 2 Results Showing Positive Outcomes For Oral Proellex® In Women With Moderate To Severe Endometriosis

Repros Provides Six Month Interim Results For Enclomiphene Study In Obese Secondary Hypogonadal Men

Repros Provides Six Month Interim Results For Enclomiphene Study In Obese Secondary Hypogonadal Men

Repros Therapeutics Inc.® Reports Second Quarter 2016 Financial Results

Repros Therapeutics Inc.® Reports Second Quarter 2016 Financial Results

8 Stocks Under $10 to Trade for Huge Profits

8 Stocks Under $10 to Trade for Huge Profits

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits

Repros Provides Update On EU Submission Of Enclomiphene For The Treatment Of Secondary Hypogonadism And 3 Month Interim Results For Enclomiphene Study In Obese Secondary Hypogonadal Men

Repros Provides Update On EU Submission Of Enclomiphene For The Treatment Of Secondary Hypogonadism And 3 Month Interim Results For Enclomiphene Study In Obese Secondary Hypogonadal Men

Repros Reports Positive Clinical Data For Oral Proellex® In Women With Severe Menstrual Bleeding Due To Uterine Fibroids

Repros Reports Positive Clinical Data For Oral Proellex® In Women With Severe Menstrual Bleeding Due To Uterine Fibroids

Repros Announces The Appointment Of Mr. Patrick Fourteau As Chairman Of The Board

Repros Announces The Appointment Of Mr. Patrick Fourteau As Chairman Of The Board

Repros Therapeutics Inc.® Reports First Quarter 2016 Financial Results

Repros Therapeutics Inc.® Reports First Quarter 2016 Financial Results

5 Stocks Under $10 Set to Soar

5 Stocks Under $10 Set to Soar

These under-$10 stock look poised to break out and trade higher from current levels.

Repros Reports Positive Clinical Data For Vaginal Proellex® In Women With Severe Menstrual Bleeding Due To Uterine Fibroids

Repros Reports Positive Clinical Data For Vaginal Proellex® In Women With Severe Menstrual Bleeding Due To Uterine Fibroids

Repros Announces Initiation Of Formal Approval Process By The European Medicines Agency

Repros Announces Initiation Of Formal Approval Process By The European Medicines Agency

Repros Therapeutics Inc.® Reports Fourth Quarter And Year End 2015 Financial Results

Repros Therapeutics Inc.® Reports Fourth Quarter And Year End 2015 Financial Results

Load More

From Our Partners

Repros Therapeutics reports Q1 results
SeekingAlpha

What's in the Cards for Repros (RPRX) this Earnings Season?
Zacks

Repros nabs new patent covering uterine disorder med Proellex; shares up 9%
SeekingAlpha

FDA continues partial clinical hold for Repros Therapeutics' fibroids drug
SeekingAlpha

Repros Therapeutics beats by $0.01
SeekingAlpha

New chief at Repros
SeekingAlpha

Healthcare - Top 5 Gainers / Losers as of 11:30 am
SeekingAlpha

Repros to Meet with the FDA for Phase III Proellex Program
Zacks

Midday Gainers / Losers
SeekingAlpha

FDA Ad Comm backs expanded criteria for drug to show clinical benefit of treatments for secondary hypogonadism
SeekingAlpha

Premarket Gainers / Losers as of 9:10 am
SeekingAlpha

Repros Therapeutics upgraded to Buy from Neutral at Ladenburg
The Fly

Premarket Gainers / Losers as of 9:10 am
SeekingAlpha

Repros (RPRX) Reports Positive Top-Line Data on Proellex
Zacks

Repros' Proellex successful in mid-stage uterine fibroid studies; shares ahead 16% after hours
SeekingAlpha

Trending
We Went to Sears for the First Time in More Than 10 Years and Instantly Saw Why It's Dying
15 Great Dividend Stocks to Own Should the Surging Stock Market Plunge This Summer
24 Large Retailers Besides J.C. Penney Are Closing Waves of Stores
6 Terrifying Companies That Have Slashed Their Dividends Or Might Very Soon
Rite Aid Stock Explodes 30% Higher on Report of FTC Approval for Walgreen's Acquisition